Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944976 | 0.87 | L3MBTL1 (0.50) | MAPTL3MBTL1ALDH1A1LMNAHTT | |
| SCHEMBL9944978 | 0.87 | L3MBTL1 (0.50) | MAPTL3MBTL1ALDH1A1LMNAHTT | |
| SCHEMBL9945035 | 0.85 | L3MBTL1 (0.54) | MAPTL3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL9944973 | 0.85 | GAA (0.46) | MAPTL3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL9944982 | 0.82 | L3MBTL1 (0.55) | MAPTL3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL9944769 | 0.81 | MAPT (0.48) | MAPTALDH1A1LMNATDP1HTT | |
| SCHEMBL9945032 | 0.81 | MAPT (0.48) | MAPTALDH1A1LMNATDP1HTT | |
| SCHEMBL9944980 | 0.80 | L3MBTL1 (0.53) | MAPTL3MBTL1ALDH1A1LMNAHTT | |
| SCHEMBL9944774 | 0.78 | L3MBTL1 (0.48) | MAPTL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9945017 | 0.77 | KMT2A (0.51) | MAPTL3MBTL1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | MAPT 4336/4885L3MBTL1 3016/4885ALDH1A1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.